Return on Tangible Equity: The amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity. Calculated as: Income from Continuing Operations / Tangible Shareholders Equity
Provectus Biopharmaceuticals, Inc. (PVCT) had Return on Tangible Equity of 22.92% for the most recently reported fiscal quarter, ending 2025-03-31.
| Income Statement Financials | |
$0.28M |
|
$-1.14M |
|
-- |
|
$0.28M |
|
$1.38M |
|
$-1.10M |
|
$-0.06M |
|
$-1.16M |
|
$-1.16M |
|
$-1.16M |
|
$-1.16M |
|
$-1.16M |
|
$-1.16M |
|
$-1.10M |
|
$-1.10M |
|
420.28M |
|
420.28M |
|
$0.00 |
|
$0.00 |
|
| Balance Sheet Financials | |
$0.65M |
|
$0.00M |
|
$0.02M |
|
$0.67M |
|
$5.74M |
|
-- |
|
-- |
|
$5.74M |
|
$-5.08M |
|
$-5.07M |
|
$-5.07M |
|
-- |
|
| Cash Flow Statement Financials | |
$-1.09M |
|
-- |
|
$1.07M |
|
$0.49M |
|
$0.47M |
|
$-0.02M |
|
$0.32M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
0.11 |
|
-- |
|
-- |
|
-- |
|
-0.51 |
|
100.00% |
|
-394.05% |
|
-394.05% |
|
-- |
|
-416.90% |
|
-409.19% |
|
$-1.09M |
|
-- |
|
-- |
|
-- |
|
0.42 |
|
-- |
|
-- |
|
-- |
|
22.85% |
|
|
Return on Tangible Equity |
22.92% |
-174.35% |
|
22.92% |
|
-- |
|
$-0.00 |
|
$-0.00 |
|